January 17, 2019

The Clinical Utility of APOL1 Mutations in Treating Chronic Kidney Disease

Can this mutation predict likelihood of transplant rejection?

650×450-Kidney-Disease

African-Americans are four times more likely than their white peers to develop chronic kidney disease (CKD) across their lifetime. African Americans also develop CKD as a comorbid condition much more often than individuals of European descent, even when controlled for other risk factors. Much of this increased risk correlates to increased genetic susceptibility, specifically mutations in the APOL1 gene found on chromosome 22 that are only found in individuals of African ancestry. Variants in APOL1 are associated with increased CKD risk.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

APOL1, which codes for an apolipoprotein, is bound to HDL3 and circulates in the bloodstream. However, APOL1 is also expressed in some kidney cells. Although the direct mechanism of nephron destruction is largely unknown, scientists believe it is at least in part due to the protein’s ability to induce apoptosis and cell necrosis. An individual must have two copies of the APOL1 risk variants to be at risk for kidney disease. In one study, up to 76 percent of individuals with two copies of the faulty allele also reported having some kind of precursor to CKD — glomerulosclerosis or nephrosclerosis — compared with only 12 percent with two low-risk alleles.

A protective mutation

Much like sickle cell trait can protect its heterozygous carriers from the ill-effects of malaria, APOL1 protects against African trypanosomiasis, or African sleeping sickness, to a degree consistent with the number of risk alleles inherited. This protective function of genetic mutation is of no use to those of African descent living far from the risk of contracting trypanosomiasis. A recent study suggests that individuals of African descent who do not identify as African (i.e., Haitian and Jamaican) have similar genetic variations, but don’t know about their risk for developing CKD. To complicate matters further, although approximately 12 percent of African-Americans carry an APOL1 risk genotype, only a subset of individuals develop CKD regardless of their genetic APOL1 variant. This makes the disease quite different from sickle cell disease because it seems to develop only in individuals who have experienced what researchers call a “second hit,” requiring stress on the organism to activate a disease state.

Predicting transplant rejection

John Sedor, MD, and John O’Toole, MD, Nephrology and Hypertension, along with Leslie Bruggeman, PhD, Inflammation and Immunity, have devoted much of their research to determining how APOL1 works in the body and how understanding the molecular basis for APOL1’s genetic association could inform treatment of CKD in the future. Currently, the clinical utility of genotyping individuals for APOL1 remains controversial, but Dr. Sedor believes that it may have the most impact in a transplantation setting.

Advertisement

“Outcome data show deceased donor kidneys with APOL1 high-risk genotypes have worse outcomes, independent of recipient APOL1 genotype,” he explains. “In addition, case studies and one retrospective cohort analysis suggest living kidney donors with the APOL1 risk genotype may also be at risk for progressive CKD. Fortunately the NIDDK [National Institute of Diabetes and Digestive and Kidney Diseases] has assembled the APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) to define the effects of variant APOL1 on living donor and allograft outcomes, which should guide us in implementing APOL1 genotyping in clinical practice.”

Emilio Poggio, MD, Director of Kidney and Pancreas Transplantation at Cleveland Clinic, leads one of the APOLLO Networks. For more information, visit APOLLO Consortium.

Related Articles

DNA
February 6, 2024
Is the MTHFR Gene Mutation Associated With Thrombosis?

The relationship between MTHFR variants and thrombosis risk is a complex issue, but current evidence points to no association between the most common variants and an elevated risk

HVI_Kelley_4277155_Patient Procedure Shoot- First in Human Trial
October 27, 2023
Cleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy

One-time infusion of adenovirus-based therapy is designed to restore heart muscle function

23-NEU-4035612-CQD-Hero-650×450
August 17, 2023
Parkinson’s Disease Research in Women (Podcast)

Studying gender-specific health factors promises new insight into diagnosis, prognosis, treatment

23-NEU-3989309-CQD-Hero-Podcast-650×450 (1)
July 3, 2023
Genetics of Parkinson’s Disease in Latino Populations (Podcast)

Consortium is uncovering risk factors that spur disease development in an understudied group

23-CCC-3620671-CQD-650×450-1
February 22, 2023
Determining Autism, Cancer Risk in Patients with PTEN Hamartoma Tumor Syndrome

Cleveland Clinic researchers receive $2 million grant from the National Institutes of Health

22-NEU-2638258 genetics_650x450
August 8, 2022
The Case for a Precision Medicine Approach to Training Epilepsy Clinicians

New Cleveland Clinic fellowship fosters expertise in the genetics of epilepsy

21-URL-2361635 CQD 650×450
June 23, 2022
Managing Refractory Hypocalcemia in an Asymptomatic Patient During Pregnancy

Renal genetic testing confirms diagnosis, guides management

22-NEU-2832861-epilepsy-evaluation-in-infant-650×450
April 6, 2022
Prediction Model Aids in the Early Diagnosis of Dravet Syndrome

Integrates genetic and clinical data to distinguish from GEFS+ and milder epilepsies

Ad